Arcutis Biotherapeutics Inc
NASDAQ:ARQT

Watchlist Manager
Arcutis Biotherapeutics Inc Logo
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
Watchlist
Price: 25.87 USD -1.75%
Market Cap: $3.2B

Net Margin

-13.9%
Current
Improving
by 1 486%
vs 3-y average of -1 499.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-13.9%
=
Net Income
$-44.3m
/
Revenue
$317.9m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-13.9%
=
Net Income
$-44.3m
/
Revenue
$317.9m

Peer Comparison

Country Company Market Cap Net
Margin
US
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
3.2B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
395.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.8B USD
Loading...

Market Distribution

Lower than 72% of companies in the United States of America
Percentile
28th
Based on 15 072 companies
28th percentile
-13.9%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Arcutis Biotherapeutics Inc
Glance View

Arcutis Biotherapeutics Inc. emerged on the biopharmaceutical scene with a focused mission: to redefine how common yet undertreated dermatological conditions are managed. Founded in California, this innovative company is dedicated to advancing treatments for wide-ranging skin diseases, including psoriasis, atopic dermatitis, and seborrheic dermatitis. Arcutis sets itself apart by concentrating on developing topical treatments, appreciating both the nuanced challenges of dermatological conditions and the substantial unmet needs in this field. The company's research and development efforts pivot around creating therapies that deliver both efficacy and safety, making them suitable for chronic use without the concerning side effects that often accompany existing treatments. Arcutis generates its revenue primarily through the successful development and subsequent commercialization of its product pipeline. By harnessing cutting-edge scientific platforms and fostering strategic collaborations, the company aims to accelerate the transition of its promising candidates from the lab to the marketplace. Revenue streams are expected to be bolstered through product sales and potentially through partnerships or licensing arrangements with larger pharmaceutical players. By addressing specific pain points within dermatology, particularly in the realm of topical applications, Arcutis is strategically positioning itself to capture significant market share in a landscape where effective solutions are in high demand yet remain limited.

ARQT Intrinsic Value
19.53 USD
Overvaluation 25%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-13.9%
=
Net Income
$-44.3m
/
Revenue
$317.9m
What is Arcutis Biotherapeutics Inc's current Net Margin?

The current Net Margin for Arcutis Biotherapeutics Inc is -13.9%, which is above its 3-year median of -1 499.9%.

How has Net Margin changed over time?

Over the last 3 years, Arcutis Biotherapeutics Inc’s Net Margin has increased from -42 571.2% to -13.9%. During this period, it reached a low of -42 571.2% on Sep 30, 2022 and a high of -13.9% on Sep 30, 2025.

Back to Top